A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.

Teresa N. Faria, Julita K. Timoszyk, Terry R. Stouch, Balvinder S. Vig, Christopher P. Landowski, Gordon L. Amidon, C. David Weaver, Doris A. Wall, Ronald L. Smith

Research output: Contribution to journalArticleScientificpeer-review

36 Citations (Scopus)

Abstract

PepT1 is a transporter of proven pharmaceutical utility for enhancing oral absorption. A high-throughput, robust functional assay, capable of distinguishing PepT1 binders from substrates, allowing identification and/or prediction of drug candidate activation was developed. An MDCK epithelial cell line was transfected with rPepT1. The high level of stable rPepT1 expression that was achieved enabled development of a miniaturized PepT1 assay in a 96-well format, which could be scaled to 384 wells. The assay is based on measurement of membrane depolarization resulting from the cotransport of protons and PepT1 substrates. Membrane potential changes are tracked with a voltage-sensitive fluorescent indicator. Control (mock-transfected) cells are used to determine nonspecific membrane potential changes. A variety of fluorescent dyes were tested during initial assay design, including intracellular pH and membrane potential indicators. A membrane potential indicator was chosen because of its superior performance. Upon PepT1 activation with glycylsarcosine, dose-dependent membrane depolarization was observed with an EC50 of 0.49 mM. Maximum depolarization was dependent on the level of PepT1 expression. Testing of 38 known PepT1 substrates, binders, and nonbinders demonstrated that this assay accurately distinguished substrates from binders and from nonbinders. Initial validation of this novel assay indicates that it is sensitive and robust, and can distinguish between transporter substrates and antagonists. This important distinction has been previously achieved only with lower-throughput assays. This assay might also be used to determine substrate potency and establish a high-quality data set for PepT1 SAR modeling.

Original languageEnglish
Pages (from-to)67-76
Number of pages10
JournalMolecular Pharmaceutics
Volume1
Issue number1
DOIs
Publication statusPublished - 1 Jan 2004
MoE publication typeA1 Journal article-refereed

Fingerprint

Membrane Potentials
Intracellular Membranes
Madin Darby Canine Kidney Cells
Membranes
Fluorescent Dyes
Protons
Epithelial Cells
Cell Line
Pharmaceutical Preparations

Cite this

Faria, Teresa N. ; Timoszyk, Julita K. ; Stouch, Terry R. ; Vig, Balvinder S. ; Landowski, Christopher P. ; Amidon, Gordon L. ; Weaver, C. David ; Wall, Doris A. ; Smith, Ronald L. / A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists. In: Molecular Pharmaceutics. 2004 ; Vol. 1, No. 1. pp. 67-76.
@article{3f82db89e0d14b75b2a68e2c3fc11220,
title = "A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.",
abstract = "PepT1 is a transporter of proven pharmaceutical utility for enhancing oral absorption. A high-throughput, robust functional assay, capable of distinguishing PepT1 binders from substrates, allowing identification and/or prediction of drug candidate activation was developed. An MDCK epithelial cell line was transfected with rPepT1. The high level of stable rPepT1 expression that was achieved enabled development of a miniaturized PepT1 assay in a 96-well format, which could be scaled to 384 wells. The assay is based on measurement of membrane depolarization resulting from the cotransport of protons and PepT1 substrates. Membrane potential changes are tracked with a voltage-sensitive fluorescent indicator. Control (mock-transfected) cells are used to determine nonspecific membrane potential changes. A variety of fluorescent dyes were tested during initial assay design, including intracellular pH and membrane potential indicators. A membrane potential indicator was chosen because of its superior performance. Upon PepT1 activation with glycylsarcosine, dose-dependent membrane depolarization was observed with an EC50 of 0.49 mM. Maximum depolarization was dependent on the level of PepT1 expression. Testing of 38 known PepT1 substrates, binders, and nonbinders demonstrated that this assay accurately distinguished substrates from binders and from nonbinders. Initial validation of this novel assay indicates that it is sensitive and robust, and can distinguish between transporter substrates and antagonists. This important distinction has been previously achieved only with lower-throughput assays. This assay might also be used to determine substrate potency and establish a high-quality data set for PepT1 SAR modeling.",
author = "Faria, {Teresa N.} and Timoszyk, {Julita K.} and Stouch, {Terry R.} and Vig, {Balvinder S.} and Landowski, {Christopher P.} and Amidon, {Gordon L.} and Weaver, {C. David} and Wall, {Doris A.} and Smith, {Ronald L.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1021/mp034001k",
language = "English",
volume = "1",
pages = "67--76",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society ACS",
number = "1",

}

Faria, TN, Timoszyk, JK, Stouch, TR, Vig, BS, Landowski, CP, Amidon, GL, Weaver, CD, Wall, DA & Smith, RL 2004, 'A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.', Molecular Pharmaceutics, vol. 1, no. 1, pp. 67-76. https://doi.org/10.1021/mp034001k

A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists. / Faria, Teresa N.; Timoszyk, Julita K.; Stouch, Terry R.; Vig, Balvinder S.; Landowski, Christopher P.; Amidon, Gordon L.; Weaver, C. David; Wall, Doris A.; Smith, Ronald L.

In: Molecular Pharmaceutics, Vol. 1, No. 1, 01.01.2004, p. 67-76.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.

AU - Faria, Teresa N.

AU - Timoszyk, Julita K.

AU - Stouch, Terry R.

AU - Vig, Balvinder S.

AU - Landowski, Christopher P.

AU - Amidon, Gordon L.

AU - Weaver, C. David

AU - Wall, Doris A.

AU - Smith, Ronald L.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - PepT1 is a transporter of proven pharmaceutical utility for enhancing oral absorption. A high-throughput, robust functional assay, capable of distinguishing PepT1 binders from substrates, allowing identification and/or prediction of drug candidate activation was developed. An MDCK epithelial cell line was transfected with rPepT1. The high level of stable rPepT1 expression that was achieved enabled development of a miniaturized PepT1 assay in a 96-well format, which could be scaled to 384 wells. The assay is based on measurement of membrane depolarization resulting from the cotransport of protons and PepT1 substrates. Membrane potential changes are tracked with a voltage-sensitive fluorescent indicator. Control (mock-transfected) cells are used to determine nonspecific membrane potential changes. A variety of fluorescent dyes were tested during initial assay design, including intracellular pH and membrane potential indicators. A membrane potential indicator was chosen because of its superior performance. Upon PepT1 activation with glycylsarcosine, dose-dependent membrane depolarization was observed with an EC50 of 0.49 mM. Maximum depolarization was dependent on the level of PepT1 expression. Testing of 38 known PepT1 substrates, binders, and nonbinders demonstrated that this assay accurately distinguished substrates from binders and from nonbinders. Initial validation of this novel assay indicates that it is sensitive and robust, and can distinguish between transporter substrates and antagonists. This important distinction has been previously achieved only with lower-throughput assays. This assay might also be used to determine substrate potency and establish a high-quality data set for PepT1 SAR modeling.

AB - PepT1 is a transporter of proven pharmaceutical utility for enhancing oral absorption. A high-throughput, robust functional assay, capable of distinguishing PepT1 binders from substrates, allowing identification and/or prediction of drug candidate activation was developed. An MDCK epithelial cell line was transfected with rPepT1. The high level of stable rPepT1 expression that was achieved enabled development of a miniaturized PepT1 assay in a 96-well format, which could be scaled to 384 wells. The assay is based on measurement of membrane depolarization resulting from the cotransport of protons and PepT1 substrates. Membrane potential changes are tracked with a voltage-sensitive fluorescent indicator. Control (mock-transfected) cells are used to determine nonspecific membrane potential changes. A variety of fluorescent dyes were tested during initial assay design, including intracellular pH and membrane potential indicators. A membrane potential indicator was chosen because of its superior performance. Upon PepT1 activation with glycylsarcosine, dose-dependent membrane depolarization was observed with an EC50 of 0.49 mM. Maximum depolarization was dependent on the level of PepT1 expression. Testing of 38 known PepT1 substrates, binders, and nonbinders demonstrated that this assay accurately distinguished substrates from binders and from nonbinders. Initial validation of this novel assay indicates that it is sensitive and robust, and can distinguish between transporter substrates and antagonists. This important distinction has been previously achieved only with lower-throughput assays. This assay might also be used to determine substrate potency and establish a high-quality data set for PepT1 SAR modeling.

UR - http://www.scopus.com/inward/record.url?scp=13944269270&partnerID=8YFLogxK

U2 - 10.1021/mp034001k

DO - 10.1021/mp034001k

M3 - Article

C2 - 15832502

AN - SCOPUS:13944269270

VL - 1

SP - 67

EP - 76

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 1

ER -